ANN ARBOR STAGE IV B-CELL NON-HODGKIN LYMPHOMA
Clinical trials for ANN ARBOR STAGE IV B-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new ANN ARBOR STAGE IV B-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for ANN ARBOR STAGE IV B-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Tiny radiation dose may tame eye lymphoma
Disease control OngoingThis study tests whether a very low dose of radiation (4 Gy) can control slow-growing B-cell lymphoma in the eye socket. About 50 adults with stage I-IV indolent lymphoma or mantle cell lymphoma will receive this targeted treatment. The goal is to shrink or stop the cancer while …
Matched conditions: ANN ARBOR STAGE IV B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New drug duo aims to control lymphoma without chemo
Disease control OngoingThis phase II trial is testing two drugs, obinutuzumab and ibrutinib, as the first treatment for people with indolent non-Hodgkin's lymphoma, a slow-growing blood cancer. The goal is to see how many patients respond to the combination. The study involves 30 participants and is no…
Matched conditions: ANN ARBOR STAGE IV B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Immunotherapy-Chemo combo shows promise in aggressive lymphoma trial
Disease control OngoingThis phase 2 trial is testing whether adding the immunotherapy drug nivolumab to a standard chemotherapy regimen (DA-REPOCH) can improve outcomes for people with aggressive B-cell non-Hodgkin lymphoma. The study enrolls 30 patients with various subtypes of the disease. The main g…
Matched conditions: ANN ARBOR STAGE IV B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC